Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!

Leonard Amaral, Martin J. Boeree, Stephen H. Gillespie, Zarir F. Udwadia, Dick van Soolingen

Research output: Contribution to journalReview articlepeer-review

84 Citations (Scopus)


Thioridazine (TDZ) has been shown to have in vitro activity against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis, to promote the killing of intracellular MDR and XDR strains and to cure the mouse of antibiotic-susceptible and -resistant pulmonary tuberculosis (TB) infections. Recently, TDZ was used to cure 10 of 12 XDR-TB patients in Buenos Aires, Argentina. At the time of writing, it is being used for the therapy of non-antibiotic-responsive terminal XDR-TB patients in Mumbai, India, on the basis of compassionate therapy and although it is too early to determine a cure, the patients have improved appetite, weight gain, are afebrile and free of night sweats, and their radiological picture shows great improvement. Because XDR-TB is essentially a terminal disease in many areas of the world and no new effective agents have yet to yield successful clinical trials, global clinical trials for the therapy of XDR-TB are urgently required. (C) 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Original languageEnglish
Pages (from-to)524-526
Number of pages3
JournalInternational Journal of Antimicrobial Agents
Issue number6
Early online date25 Feb 2010
Publication statusPublished - Jun 2010


  • Pulmonary tuberculosis
  • Multidrug-resistant TB
  • Extensively drug-resistant TB


Dive into the research topics of 'Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!'. Together they form a unique fingerprint.

Cite this